Ge Wei
25Patents
6h-index
18Co-inventors
62Inventor score
Filing activity: Dec 9, 2009 → Jul 19, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9447401B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 30 | Active |
| US9284543B2 | Neutral active soluble truncated PH20 polypeptides and uses thereof | Emerging Cross-Sectional Technologies | 28 | Active |
| US11041149B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 20 | Active |
| US11066656B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 20 | Active |
| US8927249B2 | Extended soluble PH20 polypeptides and uses thereof | Emerging Cross-Sectional Technologies | 12 | Active |
| US10865400B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 9 | Active |
| US9683985B2 | Methods for assessing and identifying or evolving conditionally active therapeutic proteins | Physics | 4 | Active |
| US12091692B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 2 | Active |
| US12104185B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US11952600B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US12018298B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US10869864B2 | Combinations for the treatment of cancer | Chemistry; Metallurgy | 1 | Active |
| US8457902B2 | Method for selecting SIRNAs from a plurality of SIRNAs for gene silencing | Physics | 0 | Active |
| US12049652B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12152262B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12195773B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12371685B2 | PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12104184B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12037618B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12054758B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12077791B2 | PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12060590B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12110520B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12123035B2 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12264345B1 | PH20 polypeptide variants, formulations and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.